CUMBERLAND PHARMACEUTICALS INCCPIXEarnings & Financial Report
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded prescription medicines. Its core product portfolio covers acute care, gastroenterology, pain management and rare disease treatment, with its primary operating market being the United States, serving healthcare providers and patients in relevant care segments.
Revenue
$9.1M
Gross Profit
$7.8M
Operating Profit
$-1.7M
Net Profit
$-1.5M
Gross Margin
85.4%
Operating Margin
-18.6%
Net Margin
-17.0%
YoY Growth
-9.9%
EPS
$-0.11
CUMBERLAND PHARMACEUTICALS INC Q3 FY2024 Financial Summary
CUMBERLAND PHARMACEUTICALS INC reported revenue of $9.1M (down 9.9% YoY) for Q3 FY2024, with a net profit of $-1.5M (down 47.2% YoY) (-17.0% margin). Cost of goods sold was $1.3M, operating expenses totaled $9.5M.
Key Financial Metrics
| Total Revenue | $9.1M |
|---|---|
| Net Profit | $-1.5M |
| Gross Margin | 85.4% |
| Operating Margin | -18.6% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
CUMBERLAND PHARMACEUTICALS INC Q3 FY2024 revenue of $9.1M breaks down across 4 segments, led by Product Kristalose at $3.6M (40.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product Kristalose | $3.6M | 40.0% |
| Product Sancuso | $2.6M | 28.7% |
| Other | $1.6M | 17.3% |
| Product Caldolor | $1.3M | 14.0% |
CUMBERLAND PHARMACEUTICALS INC Revenue by Segment — Quarterly Trend
CUMBERLAND PHARMACEUTICALS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Product Kristalose and Product Sancuso) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Product Kristalose | — | $1.2M | $2.8M | $3.5M |
| Product Sancuso | — | $3.2M | — | $2.3M |
| Other | — | $3.9M | $6.5M | $4.7M |
| Product Caldolor | — | — | $1.6M | $1.3M |
CUMBERLAND PHARMACEUTICALS INC Annual Revenue by Year
CUMBERLAND PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $44.5M |
| 2024 | $37.9M |
| 2023 | $39.6M |
| 2022 | $42.0M |
CUMBERLAND PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
CUMBERLAND PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.7M | +31.1% | $-1.4M | -10.3% |
| Q3 FY2025 | $8.3M | -8.7% | $-1.9M | -23.4% |
| Q2 FY2025 | $10.8M | +10.0% | $-740.7K | -6.8% |
| Q1 FY2025 | $11.7M | +37.8% | $1.3M | 10.7% |
| Q4 FY2024 | $10.4M | +11.6% | $-1.9M | -18.2% |
| Q3 FY2024 | $9.1M | -9.9% | $-1.5M | -17.0% |
| Q2 FY2024 | $9.8M | -9.6% | $-1.1M | -11.0% |
| Q1 FY2024 | $8.5M | -7.9% | $-1.9M | -22.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.5M | $9.8M | $9.1M | $10.4M | $11.7M | $10.8M | $8.3M | $13.7M |
| YoY Growth | -7.9% | -9.6% | -9.9% | 11.6% | 37.8% | 10.0% | -8.7% | 31.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $81.5M | $78.5M | $76.7M | $75.6M | $69.9M | $67.9M | $65.9M | $76.8M |
| Liabilities | $54.3M | $52.5M | $52.3M | $53.0M | $41.6M | $40.2M | $40.1M | $52.3M |
| Equity | $27.5M | $26.3M | $24.8M | $22.9M | $28.7M | $28.0M | $26.1M | $24.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.1M | $-855660 | $475503 | $1.9M | $3.9M | $843801 | $187180 | $3024 |